This stock rally is showing real strength, and the Street is now taking seriously the possibility of a ‘soft landing’ case, with inflation falling to the Fed’s target rate of 2% in the coming year. We view the current stock valuation as an attractive entry-point given Arrowhead’s progress in developing pulmonary-based RNAi therapies, establishing a potential first-mover advantage in large markets. Analyst Neel Mitra covers OKE stock for Bank of America, and in his view, the Magellan transaction and the new assets it brings to Oneok’s network are the key points that should interest investors.